Tardive dyskinesia (TD) is a late-appearing and sometimes persistent complication of longterm treatment with antipsychotics (AP) charakterised by abnormal postures and involuntary movements of the face or longue, trunk and extremities. We reffered the pathophisiologic hypotheses proposed to explain TD and clinical data about risk of TD in patients under treatment with classical neuroleptics and novel antipsychotics (SGA). Very few evidence-based treatment options for TD have been estabilished as effective. The strategies which has been used to help manage TD, are discussed (switch on different AP, supplementary drugs with target activity in neurotransmission and antioxidants). The results of studies suggest, that clozapine and probably SGAS suppress pre-existing TD therefore atypical antipsychotics should be the fi rst antipsychotics used in patients whe have experienced TD a result of treatment with conventional neuroleptics.